Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Similarity of Sintilimab (M1b vs Approved) in NSCLC
NCT04177290Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Apr 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of sintilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Innovent Biologics. Primary endpoint: Area Under the Curve from time zero to infinity at 28 days. Started Apr 2020; status: completed.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04177290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177290.